Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess safety and efficacy of CAT-2003 in patients with
chylomicronemia. The study will evaluate the effects of CAT-2003 on fasting total and
chylomicron triglyceride levels, as well as postprandial total and chylomicron triglyceride
clearance.
This is a single-blind study. All patients will receive placebo for 1 week, and CAT-2003 for
12 weeks during the 13 week treatment period.